Wells Fargo Initiates Coverage On Inozyme Pharma with Overweight Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Inozyme Pharma (NASDAQ:INZY) with an Overweight rating and a price target of $14.
May 30, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Inozyme Pharma with an Overweight rating and a price target of $14, indicating a positive outlook for the stock.
The initiation of coverage with an Overweight rating and a specific price target of $14 by a major financial institution like Wells Fargo is likely to boost investor confidence and positively impact the stock price of Inozyme Pharma in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100